Pharming announces completion of enrolment in Phase II/III study with leniolisib for activated PI3K delta syndrome

Pharming announces the successful completion of patient enrolment in the pivotal Phase II/III triple-blind, randomized, placebo-controlled study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). With completion of enrolment, we move one step closer to making this medicine available for APDS patients around the world. — Anurag Relan - Chief Medical Officer Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗